Although these genotypes would theoretically predict reductions in 9 and 8% for CHD risk and 14 and 12% for MI risk, these genetic variations of APOA1 did not associate with decreased risk of CHD or MI in daily practice. This evidence concerns the gene APOA1 and coronary artery disorder.